Home / Sources & Credits

Sources and credits

Text survived, images did not: here is what is sourced and what is a stand-in.

This is an independent record of Saphtx, Inc., a Newark, New Jersey company translating self-assembled peptide research into therapeutics for the back of the eye and for viral infection.

What survived. The company’s 2021 Squarespace site was archived as text — home and COVID-19 pages — but its logo and every image returned 404. The science survives in an SBIR award record, a 2019 Biomaterials abstract and a 2024 Nature Communications paper. The layout, palette and diagrams here are this rebuild’s, and the photographs are credited replacements, not the company’s.

Provenance

Where each claim comes from

  • “Who are we” — the archived saphtx.com home page, 2021: “We are a dedicated team of engineers, biologists, and inventors that have a passion for scientific innovation. We engineer protein-based therapeutic strategies for some of the biggest health issues we face. We are at the forefront of translating the innovations and inventions of engineers and scientists in Academia.”
  • The COVID-19 page — the archived /covid19 page: the standard-of-care gap, the peptide approach and the hope for a safe, inexpensive therapeutic.
  • Address, phone, email — the same site: 50 Rector Street, Newark, NJ 07102; 678-613-1386; info@saphtx.com.
  • The ocular programme — the 2019 Biomaterials Society abstract “SAPHTx: Injectable Hydrogel for Treating Neovascular Ocular Diseases” (Sarkar, Nguyen, Siddiqui, Kumar; NJIT): the monthly anti-VEGF problem, the hydrogel of naturally occurring amino acids, and the market figures.
  • The platform and the paper — “Antiviral fibrils of self-assembled peptides with tunable compositions”, Nature Communications, 7 February 2024: hetero-peptides, β-sheet fibrils, tunable composition, multivalent binding, resilience to mutation.
  • The award — the SBIR award record: NSF STTR Phase I, 2021, $255,933, contract 2032392, principal investigator Corey Heffernan, 136 4th Ave, Newark.
  • Founded 2018 — Crustdata’s company profile, which also records one employee and about $256,000 raised.

Photography

Replacement images, credited

The company’s own images are gone, so four licence-cleared photographs stand in. They are illustrations, not company data or company premises, and each is captioned where it appears.

  • Laboratory — “A group of scientists working in a laboratory”, Esculab, CC0, Wikimedia Commons. Home hero and closing band.
  • SARS-CoV-2 particles — “Novel Coronavirus SARS-CoV-2”, NIAID-RML, CC BY 2.0, Wikimedia Commons. Antiviral hero and home.
  • Eye macro — “Iris Macro, Eye close-up”, Matt Ming, CC BY 2.0, Wikimedia Commons. Ophthalmology hero.
  • Newark — “Aerial view of downtown in Newark, Essex County, New Jersey”, Famartin, CC BY-SA 4.0, Wikimedia Commons. Company hero.
  • Changes: resized and re-encoded only; each remains under its original licence.

What is not claimed

The gaps

  • No clinical data — neither programme has published trial results, and none is claimed.
  • No approval or regulatory status is claimed for anything described here.
  • No product, pricing or partner is named, because none was published.
  • No headcount or funding beyond the record — the one-employee, ~$256,000 figures are Crustdata’s, not the company’s.
  • The photographs are stock and are not of the company, its team or its science.
  • No claim that the company still trades: the domain is parked and the site is gone.

Independent site

Built from Saphtx’s published material and the published record of its science. Not affiliated with Saphtx, Inc. or the New Jersey Institute of Technology.

Back to the home page